We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Choosing Between Doublets and Triplets in mHSPC: What Is the Data?
Alicia K. Morgans, MD, MPH
How Nurses and Advanced Practice Clinicians Can Help Patients Navigate a New mHSPC Diagnosis
Stacy Walker, NP
Expert Panel: Selecting Treatment in mHSPC: Which Treatment for Which Patient?
Kelvin A. Moses, MD, PhD, FACS
Intensifying ADT in mHSPC: How to Improve Patient Outcomes and Adherence
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Expert Panel: How Does ADT Intensification for mHSPC Affect Future Therapy Options?
What Is the Current State of Disparities in Prostate Cancer Care?
What Is the Pharmacist’s Role in Managing mHSPC Doublet and Triplet Regimens?
Expert Panel: How Can We Integrate Patient Preference Data To Support Shared Decision-Making Conversations in mHSPC?
What Can I Do to Improve Care of Prostate Cancer Patients at Risk for Inequities?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Neeraj Agarwal, MD, FASCO
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
Rana McKay, MD
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Prostate Cancer: Focusing Androgen Receptor Inhibitors on High-Risk Localized & Locally Advanced Disease
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education